Published in J Natl Cancer Inst on September 06, 1995
Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas? Clin Orthop Relat Res (2015) 1.02
Well-differentiated extraskeletal osteosarcoma arising from the retroperitoneum that recurred as anaplastic spindle cell sarcoma. Case Rep Med (2010) 0.91
Extraskeletal osteosarcoma of the jaw. Skeletal Radiol (2004) 0.83
Extraskeletal osteosarcoma of the orbit. Sarcoma (1998) 0.80
Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report. Oncol Lett (2015) 0.75
Extraskeletal osteosarcoma of the hand: the role of marginal excision and adjuvant radiation therapy. Hand (N Y) (2015) 0.75
Subcutaneous extraskeletal osteosarcoma of the forearm: a case report and review of the literature. Skeletal Radiol (2016) 0.75
Phytochrome E influences internode elongation and flowering time in Arabidopsis. Plant Cell (1998) 3.17
Indian public-private partnership for skilled birth-attendance. Lancet (2008) 2.65
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
Phytochrome D acts in the shade-avoidance syndrome in Arabidopsis by controlling elongation growth and flowering time. Plant Physiol (1999) 2.42
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer (2001) 1.89
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.88
Spermatic cord sarcoma: outcome, patterns of failure and management. J Urol (2001) 1.88
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation (1999) 1.82
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol (2012) 1.81
A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. Am J Med (2000) 1.72
Clinical and radiological evidence to support superficial parotidectomy as the treatment of choice for chronic parotid sialadenitis: a retrospective study. Br J Oral Maxillofac Surg (2001) 1.68
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer (1995) 1.65
Effect of increased lung volume on sleep disordered breathing in patients with sleep apnoea. Thorax (2006) 1.62
Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg (1990) 1.59
Providing skilled birth attendants and emergency obstetric care to the poor through partnership with private sector obstetricians in Gujarat, India. Bull World Health Organ (2009) 1.54
Soft tissue sarcomas of the head and neck in adolescents and adults. Am J Surg (1986) 1.50
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Adriamycin cardiomyopathy--risk factors. Cancer (1977) 1.46
Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol (1999) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol (1998) 1.45
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther (2011) 1.43
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol (2010) 1.42
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Identification of patient safety improvement targets in successful vascular and endovascular procedures: analysis of 251 hours of complex arterial surgery. Eur J Vasc Endovasc Surg (2011) 1.40
Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg (1998) 1.37
Combination chemotherapy in adult desmoid tumors. Cancer (1993) 1.36
Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res (1977) 1.36
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol (1997) 1.34
Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer (1999) 1.31
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther (2012) 1.31
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. Radiother Oncol (1999) 1.29
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol (1984) 1.28
Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery (1994) 1.28
Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest (1997) 1.27
Doxorubicin-induced congestive heart failure in adults. Cancer (1985) 1.26
Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol (1999) 1.25
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer (1993) 1.25
Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol (1997) 1.25
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int (2009) 1.22
Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. Cancer Treat Rep (1977) 1.21
Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA (1988) 1.20
Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther (1973) 1.19
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol (1994) 1.17
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol (2001) 1.17
Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol (1995) 1.15
Myxoid liposarcoma. Experience with chemotherapy. Cancer (1994) 1.13
Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer (1993) 1.09
Arterial occlusion: management of giant cell tumor and aneurysmal bone cyst. AJR Am J Roentgenol (1981) 1.09
Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer (1996) 1.05
Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol (1997) 1.04
Transferability and fine-mapping of glucose and insulin quantitative trait loci across populations: CARe, the Candidate Gene Association Resource. Diabetologia (2012) 1.03
Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors. Cancer (1990) 1.03
Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer (2001) 1.02
Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 1.01
Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.01
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol (1995) 1.00
Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol (1982) 1.00
Reporting and concordance of methodologic criteria between abstracts and articles in diagnostic test studies. J Gen Intern Med (2000) 0.99
Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol (1994) 0.99
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol (1992) 0.99
Waiting for microbiologic data to direct therapy against nosocomial infections in febrile surgical patients: are outcomes worsened? Arch Surg (1999) 0.98
Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. Ann Thorac Surg (1991) 0.98
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep (1979) 0.98
Ectopic production of the beta-subunit of human chorionic gonadotropin in osteosarcoma. Arch Pathol Lab Med (1989) 0.98
Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg (2000) 0.97
Role of Sertoli cells in injury-associated testicular germ cell apoptosis. Proc Soc Exp Biol Med (2000) 0.97
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol (1995) 0.97
Sarcoma of the stomach: clinicopathologic study of 43 cases. J Surg Oncol (1980) 0.97
A phase II trial of taxol in metastatic melanoma. Cancer (1990) 0.97
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol (2000) 0.96
The natural history of resectable metastatic melanoma (Stage IVA melanoma). Cancer (1982) 0.96
A 15-year experience with chemotherapy of patients with paraganglioma. Cancer (1995) 0.96
Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res (1983) 0.95
Primary soft tissue sarcoma of the breast. Curr Treat Options Oncol (2001) 0.95
The natural history of metastatic synovial sarcoma: experience of the Southwest Oncology group. Clin Orthop Relat Res (1982) 0.94
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res (1984) 0.94
Successful treatment of hypoglycemia using glucagon in a patient with an extrapancreatic tumor. Ann Intern Med (1990) 0.93
Recovery of sperm production after chemotherapy for osteosarcoma. Cancer (1989) 0.92
Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J (1997) 0.92
Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol (1982) 0.92
Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol (1995) 0.91
A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol (1989) 0.91
Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep (1980) 0.90
Soft-tissue sarcoma of the extremities. MR appearance of post-treatment changes and local recurrences. Magn Reson Imaging Clin N Am (1995) 0.90
Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg (1998) 0.90